EP0942744A1 - Treatment of bone fracture - Google Patents
Treatment of bone fractureInfo
- Publication number
- EP0942744A1 EP0942744A1 EP97946311A EP97946311A EP0942744A1 EP 0942744 A1 EP0942744 A1 EP 0942744A1 EP 97946311 A EP97946311 A EP 97946311A EP 97946311 A EP97946311 A EP 97946311A EP 0942744 A1 EP0942744 A1 EP 0942744A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pth
- pthrp
- antagonist
- peptide
- administered parenterally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000010392 Bone Fractures Diseases 0.000 title claims abstract description 9
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims abstract description 68
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims abstract description 67
- 239000005557 antagonist Substances 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000011164 ossification Effects 0.000 claims abstract description 3
- 230000001737 promoting effect Effects 0.000 claims abstract description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 76
- 229940083963 Peptide antagonist Drugs 0.000 claims description 8
- 102100036893 Parathyroid hormone Human genes 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 18
- 239000000203 mixture Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 7
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 5
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 102000058004 human PTH Human genes 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- YKGRXSLQYRREKO-DFOPOJAZSA-N 101380-54-5 Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 YKGRXSLQYRREKO-DFOPOJAZSA-N 0.000 description 4
- 101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 inositol triphosphates Chemical class 0.000 description 3
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 description 2
- 101001135735 Rattus norvegicus Parathyroid hormone-related protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 101710149426 Parathyroid hormone 2 receptor Proteins 0.000 description 1
- 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 description 1
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 101150007503 rps1 gene Proteins 0.000 description 1
- 101150008822 rpsA gene Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
Definitions
- Parathyroid hormone is a polypeptide produced by the parathyroid glands. The mature circulating form of the hormone is comprised of 84 amino acid residues. The biological action of PTH can be reproduced by a peptide fragment of its N-terminus (e.g., amino acid residues 1 through 34) .
- Parathyroid hormone- related protein (“PTHrP”) is a 139 to 173 amino acid- protein with N-terminal homology to PTH. PTH and PTHrP bind to an identical receptor, the PTH/PTHrP receptor, expressed in kidneys and bone cells (Schipani, E. , et al., Endocrinology 132:2157-2165 (1993)).
- PTH also binds to the recently cloned PTH2 receptor (Usdin, T.B., et al., J. Biol. Chem., 270:15455-15458 (1995)), while PTHrP has a much lower affinity for this receptor.
- the binding of PTH or PTHrP to the PTH/PTHrP receptor results in intracellular accumulation of cAMP and inositol triphosphates and increases intracellular free calcium (Abou-Samra, A-B, et al., Proc. Natl. Acad. Sci. USA 89:2732-2736 (1992)).
- PTH and PTHrP agonists increase Vit D3 conversion in the kidneys, enhance reabsorption of calcium from the renal tubules, and increase calcium absorption from the gut (In: The Parathyroids-Basic and Clinic Concepts, Eds. Bilezikian, J.P., Marcus, R. , Levine, M.A., Raven Press, 1994) .
- the following invention relates to the novel discovery that a PTH/PTHrP antagonist can stimulate bone growth during fracture.
- the invention features a method of promoting bone formation at a bone fracture site in a subject (e.g., a mammal such as a human) .
- the method includes the step of administering (e.g., intravenously, subcutaneously, transmucosally, transdermally, by inhalation, orally, or by release from a sustained release formulation) to the subject a therapeutically effective amount of a PTH/PTHrP antagonist.
- PTH/PTHrP antagonist will be defined below. A therapeutically effective amount depends upon the condition being treated, the route of administration chosen, and the specific activity of the compound used and ultimately will be decided by the attending physician or veterinarian.
- the PTH/PTHrP antagonist may be administered locally to the site of the fracture or administered systemically to the subject.
- the PTH/PTHrP antagonist may also be administered intermittently or continuously to the subject.
- the PTH/PTHrP antagonist is administered to the subject until the bone fracture has healed.
- the PTH/PTHrP antagonist may be injected parenterally, e.g., subcutaneously, into the bloodstream of the subject being treated.
- the route such as intravenous, intramuscular, intraperitoneal, enterally, transdermally, transmucously, parenteral release from a sustained released polymer composition (e.g., a lactic acid polymer or lactic- glycolic acid copolymer microparticle or implant) , profusion, nasal, oral, etc., will vary with the condition being treated and the activity and bioavailability of the PTH/PTHrP antagonist being used.
- a sustained released polymer composition e.g., a lactic acid polymer or lactic- glycolic acid copolymer microparticle or implant
- the PTH/PTHrP antagonist While it is possible for the PTH/PTHrP antagonist to be administered as the pure or substantially pure compound, it may also be presented as a pharmaceutical formulation or preparation.
- the formulations to be used in the present invention, for both humans and animals, comprise any of the PTH/PTHrP antagonists to be described below, together with one or more pharmaceutically acceptable carriers thereof, and optionally other therapeutic ingredients.
- the carrier must be "acceptable” in the sense of being compatible with the active ingredient(s) of the formulation (e.g., capable of stabilizing peptides) and not deleterious to the subject to be treated.
- the formulation should not include oxidizing agents or other substances with which certain ingredients (e.g., peptides) are known to be incompatible. Consequently, it is important to carefully select the excipient. pH is another key factor, and it may be necessary to buffer the product under slightly acidic conditions (pH 5 to 6) .
- formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient(s) into association with the carrier which constitutes one or more accessory ingredients.
- the formulations for tablets or powders are prepared by uniformly and intimately blending the active ingredient with finely divided solid carriers, and then, if necessary, as in the case of tablets, forming the product into the desired shape and size.
- Formulations suitable for parenteral (e.g., intravenous) administration conveniently comprise sterile aqueous solutions of the active ingredient(s) .
- the solutions are isotonic with the blood of the subject to be treated.
- Such formulations may be conveniently prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering said solution sterile.
- the formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
- Formulations suitable for sustained release parenteral administrations e.g., biodegradable polymer formulations
- a bone resorption inhibiting agent can also be administered during performance of the above described method.
- the term “inhibition of bone resorption” refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or metabolism.
- the term “inhibitor of bone resorption” as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or metabolism.
- Suitable bone resorption inhibiting agents includes, but is not limited to, an estrogen, a bisphosphonate (e.g., PamidronateTM, CilodronateTM, IbandoronateTM, ElendronateTM, or RecidronateTM) , sodium fluoride, vitamin D, a calcitonin, and calcium.
- an estrogen e.g., PamidronateTM, CilodronateTM, IbandoronateTM, ElendronateTM, or RecidronateTM
- sodium fluoride e.g., sodium fluoride, vitamin D, a calcitonin, and calcium.
- PTH and PTHrP includes specie homologs of PTH and PTHrP, e.g., human PTH (hPTH) , bovine PTH (bPTH) , rat PTH (rPTH) , human PTHrP (hPTHrP) , and rat PTHrP (rPTHrP) .
- the sequence of various specie homologs of PTH and PTHrP are recited in Nissenson, et al., Receptor 3:193 (1993).
- a PTH/PTHrP antagonist is a compound which both binds to the PTH/PTHrP receptor and inhibits PTH/PTHrP stimulated mobilization of calcium and/or PTH/PTHrP stimulated mobilization of adenylate cyclase, i.e., as described in the biological assays described herein.
- the PTH/PTHrP antagonist is a peptide.
- Such a peptide may be a homologous (e.g., at least 70 percent homology) fragment of PTH (a "PTH peptide antagonist") or PTHrP (a "PTHrP peptide antagonist”) .
- the first four to the first seven amino acids of the N-terminus of the homologous PTH/PTHrP may be deleted.
- antagonists include hPTH(7- 34)NH 2 , bPTH(7-34)NH 2 , hPTHrP(7-34)NH 2 , [Nle 8 ' 18 , Tyr 3 ]hPTH(7-34)NH 2 , [Nle 8 ' 18 , Tyr 34 ]bPTH(7-34)NH 2 , [Nle 8 ' 18 , D-Trp 12 , Tyr 34 ]bPTH(7-34)NH 2 , and [Leu 11 , D- Trp 12 ]bPTH(7-34)NH 2 , (where the number in parentheses corresponding to the amino acid of the natural peptide which are present in the peptide, the symbol NH 2 denotes the amidation of the carboxyl group of the C-terminal amino acid to form -CONH 2 , and the numbered amino acids in the brackets refer
- the PTH/PTHrP antagonist is a non-peptide (e.g., a peptidomimetic).
- Human osteogenic sarcoma SaOS-2 cells (ATCC No. HTB85) , expressing the PTH/PTHrP receptor, were maintained in RPM1 1640 medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 37sc in a humidified atmosphere of 5% C0 2 in air. The medium was changed every three or four days, and the cells were subcultured every week by trypsinization.
- RPM1 1640 medium Sigma, St. Louis, MO
- FBS fetal bovine serum
- 2 mM glutamine 2 mM glutamine
- SaOS 2 cells were maintained for four days until they had reached confluence.
- the medium was replaced with 5% FBS in RPS1 1640 medium and incubated for 2 hrs at room temperature with 10 x 10 4 cpm [Nle 8 ' 18 , Tyr 34 (3- I 125 ) ]bPTH 1 _ 34 NH 2 in the presence of a competing test PTH/PTHrP antagonist at varying concentrations (i.e., 10 " n ito 10 ⁇ 4 m) .
- the cells were washed four times with ice-cold PBS and lysed with 0.1 M NaOH, and the radioactivity associated with the cells was counted in a scintillation counter.
- the IC 50 value (half maximal inhibition of binding of [Nle 8 ' 18 , Tyr 34 (3- 125 l) ]bPTH(l- 34)NH 2 can be calculated for each peptide.
- Synthesis of the radiolabelled [Nle 8 ' 18 , Tyr 34 (3-I 125 ) ]bPTH 1 _ 34 NH 2 was carried out as described in Goldman, ME, et al., Endocrinology, 1988, 123, 1468-1475. Cells such as the human kidney 293 cells transfected with the PTH/PTHrP receptor may also be used as described in Pines, et al., Endocrinology 135:1713 (1994).
- test PTH/PTHrP antagonists to inhibit adenylate cyclase release in response to PTH/PTHrP stimulation was also measured in SaOS-2 cells. More specifically, an inhibition of the adenylate cyclase was determined by measuring the level of synthesis of cAMP (adenosine 3' ,5'-monophosphate) . Confluent SaOS-2 cells in 24 wells plates are incubated with 0.5 ⁇ Ci[ 3 H]adenine (26.9 Ci/mmol, New England Nuclear,
- test PTH/PTHrP antagonists to inhibit calcium mobilization in response to PTH/PTHrP stimulation can also be measured in SaOS-2 cells.
- Confluent SaOS-2 BIO cells in 24 wells plates are incubated in 0.3 percent EDTA/phosphate buffered saline solution at 25sc for 2 hrs, and washed twice with Hank's solution.
- the cells are resuspended in Hank's buffered saline solution for loading of the fluorescent Ca 2+ indicator Fura-2AM.
- the cells are incubated with 2 mM fluorescent Ca 2+ indicator Fura-2AM (Molecular Probes,
- the IC 50 's (half maximal concentration for the inhibition of calcium mobilization) can be calculated for the PTH/PTHrP antagonists.
- Cells, such as human kidney 293 cells, which are transfected with the PTH/PTHrP receptor may also be used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention features a method of promoting bone formation at a bone fracture site in a subject. The method includes the step of administering to the subject a therapeutically effective amount of a PTH/PTHrP antagonist.
Description
TREATMENT OF BONE FRACTURE
Background of the Invention Parathyroid hormone ("PTH") is a polypeptide produced by the parathyroid glands. The mature circulating form of the hormone is comprised of 84 amino acid residues. The biological action of PTH can be reproduced by a peptide fragment of its N-terminus (e.g., amino acid residues 1 through 34) . Parathyroid hormone- related protein ("PTHrP") is a 139 to 173 amino acid- protein with N-terminal homology to PTH. PTH and PTHrP bind to an identical receptor, the PTH/PTHrP receptor, expressed in kidneys and bone cells (Schipani, E. , et al., Endocrinology 132:2157-2165 (1993)). In contrast, PTH also binds to the recently cloned PTH2 receptor (Usdin, T.B., et al., J. Biol. Chem., 270:15455-15458 (1995)), while PTHrP has a much lower affinity for this receptor. The binding of PTH or PTHrP to the PTH/PTHrP receptor results in intracellular accumulation of cAMP and inositol triphosphates and increases intracellular free calcium (Abou-Samra, A-B, et al., Proc. Natl. Acad. Sci. USA 89:2732-2736 (1992)).
PTH and PTHrP agonists increase Vit D3 conversion in the kidneys, enhance reabsorption of calcium from the renal tubules, and increase calcium absorption from the gut (In: The Parathyroids-Basic and Clinic Concepts, Eds. Bilezikian, J.P., Marcus, R. , Levine, M.A., Raven Press, 1994) . PTH and PTHrP agonists administered intermittently to animals and man augment bone mass, prevent bone loss in osteopenic states, and build new bone in established osteopenia (Dempster, D.W., et al., Endocrine Rev. 14:690-709 (1993); and Leaffer, D. , et al., Endocrinology 3624-3631 (1995)). The following
invention relates to the novel discovery that a PTH/PTHrP antagonist can stimulate bone growth during fracture.
Summary of the Invention The invention features a method of promoting bone formation at a bone fracture site in a subject (e.g., a mammal such as a human) . The method includes the step of administering (e.g., intravenously, subcutaneously, transmucosally, transdermally, by inhalation, orally, or by release from a sustained release formulation) to the subject a therapeutically effective amount of a PTH/PTHrP antagonist.
Definition of "PTH/PTHrP antagonist" will be defined below. A therapeutically effective amount depends upon the condition being treated, the route of administration chosen, and the specific activity of the compound used and ultimately will be decided by the attending physician or veterinarian.
The PTH/PTHrP antagonist may be administered locally to the site of the fracture or administered systemically to the subject. The PTH/PTHrP antagonist may also be administered intermittently or continuously to the subject. In one embodiment, the PTH/PTHrP antagonist is administered to the subject until the bone fracture has healed. The PTH/PTHrP antagonist may be injected parenterally, e.g., subcutaneously, into the bloodstream of the subject being treated. However, it will be readily appreciated by those skilled in the art that the route, such as intravenous, intramuscular, intraperitoneal, enterally, transdermally, transmucously, parenteral release from a sustained released polymer composition (e.g., a lactic acid polymer or lactic- glycolic acid copolymer microparticle or implant) , profusion, nasal, oral, etc., will vary with the
condition being treated and the activity and bioavailability of the PTH/PTHrP antagonist being used.
While it is possible for the PTH/PTHrP antagonist to be administered as the pure or substantially pure compound, it may also be presented as a pharmaceutical formulation or preparation. The formulations to be used in the present invention, for both humans and animals, comprise any of the PTH/PTHrP antagonists to be described below, together with one or more pharmaceutically acceptable carriers thereof, and optionally other therapeutic ingredients.
The carrier must be "acceptable" in the sense of being compatible with the active ingredient(s) of the formulation (e.g., capable of stabilizing peptides) and not deleterious to the subject to be treated. Desirably, the formulation should not include oxidizing agents or other substances with which certain ingredients (e.g., peptides) are known to be incompatible. Consequently, it is important to carefully select the excipient. pH is another key factor, and it may be necessary to buffer the product under slightly acidic conditions (pH 5 to 6) .
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient(s) into association with the carrier which constitutes one or more accessory ingredients.
In general, the formulations for tablets or powders are prepared by uniformly and intimately blending the active ingredient with finely divided solid carriers, and then, if necessary, as in the case of tablets, forming the product into the desired shape and size.
Formulations suitable for parenteral (e.g., intravenous) administration, on the other hand, conveniently comprise sterile aqueous solutions of the
active ingredient(s) . Preferably, the solutions are isotonic with the blood of the subject to be treated. Such formulations may be conveniently prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering said solution sterile. The formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials. Formulations suitable for sustained release parenteral administrations (e.g., biodegradable polymer formulations) are also well known in the art. See, e.g., U.S. Patent Nos. 3,773,919 and 4,767,628 and PCT Publication No. WO 94/15587.
Also, if desired, a bone resorption inhibiting agent can also be administered during performance of the above described method. The term "inhibition of bone resorption" refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or metabolism. Thus, the term "inhibitor of bone resorption" as used herein refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or metabolism. An example of suitable bone resorption inhibiting agents includes, but is not limited to, an estrogen, a bisphosphonate (e.g., Pamidronate™, Cilodronate™, Ibandoronate™, Elendronate™, or Recidronate™) , sodium fluoride, vitamin D, a calcitonin, and calcium.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments and from the claims.
Detailed Description of the Invention
It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.
PTH/PTHrP Antagonist
The term PTH and PTHrP includes specie homologs of PTH and PTHrP, e.g., human PTH (hPTH) , bovine PTH (bPTH) , rat PTH (rPTH) , human PTHrP (hPTHrP) , and rat PTHrP (rPTHrP) . The sequence of various specie homologs of PTH and PTHrP are recited in Nissenson, et al., Receptor 3:193 (1993). What is meant by a PTH/PTHrP antagonist is a compound which both binds to the PTH/PTHrP receptor and inhibits PTH/PTHrP stimulated mobilization of calcium and/or PTH/PTHrP stimulated mobilization of adenylate cyclase, i.e., as described in the biological assays described herein. In one embodiment, the PTH/PTHrP antagonist is a peptide. Such a peptide may be a homologous (e.g., at least 70 percent homology) fragment of PTH (a "PTH peptide antagonist") or PTHrP (a "PTHrP peptide antagonist") . The first four to the first seven amino acids of the N-terminus of the homologous PTH/PTHrP may be deleted. Examples of such antagonists include hPTH(7- 34)NH2, bPTH(7-34)NH2, hPTHrP(7-34)NH2, [Nle8' 18, Tyr3 ]hPTH(7-34)NH2, [Nle8' 18, Tyr34]bPTH(7-34)NH2, [Nle8' 18, D-Trp12, Tyr34]bPTH(7-34)NH2, and [Leu11, D-
Trp12]bPTH(7-34)NH2, (where the number in parentheses corresponding to the amino acid of the natural peptide which are present in the peptide, the symbol NH2 denotes the amidation of the carboxyl group of the C-terminal amino acid to form -CONH2, and the numbered amino acids in the brackets refer to substitutions to the natural sequence at the recited number position) . Examples of such antagonists are recited in the following patent applications: U.S. Patent Nos. 5,093,233; 4,968,669; 5,001,223; 4,771,124; 4,423,037; 5,087,562; and 5,114,843 and European Patent Application Nos. 341,963; 293,160; 293,158; 293,130; 293,159; and 341,961. In another embodiment, the PTH/PTHrP antagonist is a non-peptide (e.g., a peptidomimetic).
Synthesis of PTH/PTHrP Antagonists
The methods for synthesizing PTH/PTHrP antagonists are well documented and are within the ability of a person of ordinary skill in the art. Synthesis of short amino acid sequences is well established in the peptide art. For example, U.S. Patent No. 5,093,233 describes the synthesis of PTH antagonists while U.S. Patent No. 5,114,843 describes the synthesis of PTHrP antagonists.
PTH/PTHrP Antagonist Binding Assay
Human osteogenic sarcoma SaOS-2 cells (ATCC No. HTB85) , expressing the PTH/PTHrP receptor, were maintained in RPM1 1640 medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 37sc in a humidified atmosphere of 5% C02 in air. The medium was changed every three or four days, and the cells were subcultured every week by trypsinization.
SaOS2 cells were maintained for four days until they had reached confluence. The medium was replaced
with 5% FBS in RPS1 1640 medium and incubated for 2 hrs at room temperature with 10 x 104 cpm [Nle8'18, Tyr34(3- I125) ]bPTH1_34 NH2 in the presence of a competing test PTH/PTHrP antagonist at varying concentrations (i.e., 10" n ito 10~4m) . The cells were washed four times with ice-cold PBS and lysed with 0.1 M NaOH, and the radioactivity associated with the cells was counted in a scintillation counter. The IC50 value (half maximal inhibition of binding of [Nle8'18, Tyr34(3-125l) ]bPTH(l- 34)NH2 can be calculated for each peptide. Synthesis of the radiolabelled [Nle8'18, Tyr34 (3-I125) ]bPTH1_34NH2 was carried out as described in Goldman, ME, et al., Endocrinology, 1988, 123, 1468-1475. Cells such as the human kidney 293 cells transfected with the PTH/PTHrP receptor may also be used as described in Pines, et al., Endocrinology 135:1713 (1994).
Adenylate Cyclase Inhibition Assay
The ability of the test PTH/PTHrP antagonists to inhibit adenylate cyclase release in response to PTH/PTHrP stimulation was also measured in SaOS-2 cells. More specifically, an inhibition of the adenylate cyclase was determined by measuring the level of synthesis of cAMP (adenosine 3' ,5'-monophosphate) . Confluent SaOS-2 cells in 24 wells plates are incubated with 0.5 μCi[3H]adenine (26.9 Ci/mmol, New England Nuclear,
Boston, MA) in fresh medium at 372C for 2 hrs, and washed twice with Hank's balanced salt solution (Gibco, Gaithersberg, MD) . The cells are treated with 1 mM IBMX (isobutylmethylxanthine, Sigma, St. Louis, MO) in fresh medium for 15 min. The test PTH/PTHrP antagonist, at varying concentrations, followed by PTH, PTHrP, or a PTH or PTHrP agonist (e.g., hPTH(l-34)NH2 or [Nle8'18,Tyr34]bPTH(l-34) NH2) at a concentration approximate to its EC50 are added to the medium and
incubated for 5 min. The reaction is stopped by the addition of 1.2 M trichloroacetic acid (Sigma) followed by sample neutralization with 4 N KOH. Cyclic AMP is isolated by the two-column chromatographic method. See Salomon, et al., Anal. Biochem. 58:541 (1974). The radioactivity is counted in a scintillation counter (Liquid scintillation counter 2200CA, PACKARD, Downers Grove, IL) . The IC50's (half maximal concentration for the inhibition of adenylate cyclase release ) can be calculated for each of the test PTH/PTHrP antagonists. Cells, such as human kidney 293 cells, which are transfected with the PTH/PTHrP receptor, may also be used as described in Pines, et al., Endocrinology 35:1713 (1994) .
Calcium Inhibition Assay
The ability of the test PTH/PTHrP antagonists to inhibit calcium mobilization in response to PTH/PTHrP stimulation can also be measured in SaOS-2 cells. Confluent SaOS-2 BIO cells in 24 wells plates are incubated in 0.3 percent EDTA/phosphate buffered saline solution at 25sc for 2 hrs, and washed twice with Hank's solution. The cells are resuspended in Hank's buffered saline solution for loading of the fluorescent Ca2+ indicator Fura-2AM. The cells are incubated with 2 mM fluorescent Ca2+ indicator Fura-2AM (Molecular Probes,
Eugene, OR) in fresh medium for 30 min at 25sc. Unloaded Fura-2AM is removed by centrifugation twice with Hank's - buffered saline solution, and the final cell suspensions is transformed to a spectrofluorometer (Hitachi F-2000, Japan) , equipped with a magnetic stirring mechanism and a temperature regulated cuvette holder after equilibration to 372C, the test PTH/PTHrP antagonist, at various concentrations, followed by PTH, PTHrP, or a PTH or PTHrP agonist (at a concentration approximate to its EC50) are
added to the medium and incubated for 5 min. The IC50's (half maximal concentration for the inhibition of calcium mobilization) can be calculated for the PTH/PTHrP antagonists. Cells, such as human kidney 293 cells, which are transfected with the PTH/PTHrP receptor may also be used.
Other Embodiments The foregoing description has been limited to specific embodiments of this invention. It will be apparent, however, that variations and modifications may be made to the invention, with the attainment of some or all of the advantages of the invention. Such embodiments are also within the scope of the following claims.
What is claimed is:
Claims
1. A method of promoting bone formation at a bone fracture site in a subject, said method comprising the step of administering to said patient a therapeutically effective amount of a PTH/PTHrP antagonist.
2. A method of claim 1, wherein said PTH antagonist or said PTHrP antagonist is administered locally to said fracture site.
3. A method of claim 1, wherein said PTH/PTHrP antagonist is administered systemically to said patient.
4. A method of claim 1, wherein said PTH/PTHrP antagonist is a PTH peptide antagonist.
5. A method of claim 1, wherein said PTH/PTHrP antagonist is a PTHrP peptide antagonist.
6. A method of claim 2, wherein said PTH/PTHrP antagonist is a PTH peptide antagonist.
7. A method of claim 2, wherein said PTH/PTHrP antagonist is a PTHrP peptide antagonist.
8. A method of claim 3, wherein said PTH/PTHrP antagonist is a PTH peptide antagonist.
9. A method of claim 3, wherein said PTH/PTHrP antagonist is a PTHrP peptide antagonist.
10. A method of claim 1, wherein said PTH/PTHrP antagonist is administered parenterally.
11. A method of claim 2, wherein said PTH/PTHrP antagonist is administered parenterally.
12. A method of claim 3 , wherein said PTH/PTHrP antagonist is administered parenterally.
13. A method of claim 4 , wherein said PTH/PTHrP antagonist is administered parenterally.
14. A method of claim 5, wherein said PTH/PTHrP antagonist is administered parenterally.
15. A method of claim 6, wherein said PTH/PTHrP antagonist is administered parenterally.
16. A method of claim 7, wherein said PTH/PTHrP antagonist is administered parenterally.
17. A method of claim 8, wherein said PTH/PTHrP antagonist is administered parenterally.
18. A method of claim 9, wherein said PTH/PTHrP antagonist is administered parenterally.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76085396A | 1996-12-05 | 1996-12-05 | |
US760853 | 1996-12-05 | ||
PCT/US1997/019370 WO1998024471A1 (en) | 1996-12-05 | 1997-10-28 | Treatment of bone fracture |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0942744A1 true EP0942744A1 (en) | 1999-09-22 |
Family
ID=25060364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97946311A Withdrawn EP0942744A1 (en) | 1996-12-05 | 1997-10-28 | Treatment of bone fracture |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0942744A1 (en) |
AU (1) | AU5150798A (en) |
CA (1) | CA2273843A1 (en) |
WO (1) | WO1998024471A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114843A (en) * | 1988-05-09 | 1992-05-19 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists |
US5093233A (en) * | 1990-04-25 | 1992-03-03 | Merck & Co., Inc. | Antagonists with position 13 modification |
TW273513B (en) * | 1993-10-27 | 1996-04-01 | Chugai Pharmaceutical Co Ltd |
-
1997
- 1997-10-28 WO PCT/US1997/019370 patent/WO1998024471A1/en not_active Application Discontinuation
- 1997-10-28 AU AU51507/98A patent/AU5150798A/en not_active Abandoned
- 1997-10-28 CA CA002273843A patent/CA2273843A1/en not_active Abandoned
- 1997-10-28 EP EP97946311A patent/EP0942744A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9824471A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU5150798A (en) | 1998-06-29 |
CA2273843A1 (en) | 1998-06-11 |
WO1998024471A1 (en) | 1998-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5747456A (en) | Continuous low-dose administration of parathyroid hormone or its agonist | |
EP0917537B1 (en) | Novel parathyroid hormone-related peptide analogs | |
US7632811B2 (en) | Analogs of parathyroid hormone | |
US7410948B2 (en) | Analogs of parathyroid hormone | |
EP0948541B1 (en) | Analogs of PTHrP | |
NICKOLS et al. | Binding of parathyroid hormone and parathyroid hormone-related protein to vascular smooth muscle of rabbit renal microvessels | |
US9492508B2 (en) | Parathyroid hormone analogs and uses thereof | |
US6541450B1 (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
JP4837888B2 (en) | Conformationally restricted parathyroid hormone (PTH) analog | |
CZ291382B6 (en) | Peptide derivatives influencing growth hormone release, pharmaceutical composition containing them and their use | |
Malluche et al. | Influence of the parathyroid glands on bone metabolism | |
Östenson et al. | Effects of porcine diazepam-binding inhibitor on insulin and glucagon secretion in vitro from the rat endocrine pancreas | |
JPH10511095A (en) | Low dose continuous administration of parathyroid hormone or its agonist | |
EP0942744A1 (en) | Treatment of bone fracture | |
CACABELOS et al. | Time-and dose-dependent responses of brain histamine to intracerebroventricular and intraperitoneal administrations of growth hormone-releasing factor (GRF1-44) | |
RABBANIS et al. | Influence of the Amino-Terminus on in Vitro and in Vivo Biological Activity of Synthetic Parathyroid Hormone-Like Peptides of Malignancy | |
EP1352912A1 (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
CZ20003999A3 (en) | PTH analog, method for selective binding to receptor, method of inducing agonistic and antagonistic response, pharmaceutical preparation and therapy method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990621 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010502 |